Allergy Immunotherapy Market to Reach Valuation of USD 3.33 Billion by 2030 – Rising Prevalence of Allergic Disorders and their Burden Across the Globe Drives the Market

In terms of revenue, the Global Allergy Immunotherapy Market is expected to reach by 2030, growing at a CAGR (Compound Annual Growth Rate) of 9.2% from 2023 to 2030.

Allergy Immunotherapy involves giving specific allergens to people with conditions where their immune system overreacts. The intention is to protect them from allergens such as dust mites, pollen, and insects, which may lead to inflammatory and allergy symptoms. The increasing exposure to different allergens is driving the demand for these therapies. Sneezing and a runny nose are frequent symptoms of allergic rhinitis, which can affect many children and adults worldwide. In the UK, many adults and kids experience allergic rhinitis.

The market for Allergy Immunotherapy is growing because key players are investing in developing new treatments for the growing number of people with allergies. Government support is also essential for developing and releasing these products for previously untreated allergic conditions. ALK's clinical trial, which commenced in April 2021, exemplifies advancements in this field by examining the efficacy and safety of sublingual immunotherapy tablets in treating children and adolescents suffering from birch pollen-induced allergic rhinitis. The increasing awareness of patients worldwide also contributes to the global market for Allergy Immunotherapy.

Key Highlights from the Report

• Based on the Type segmentation, Sublingual Immunotherapy (SLIT) segment is expected to mention the fastest growth of the market during the projected time frame owing to its vital alternative for patients who cannot receive allergy shots.
• Furthermore, based on the segmentation of Allergy Type, the Allergic Asthma segment is predicted to express maximum market share during the forecast period because of a surge in production of AIT drugs by key players to treat various allergies.
• In addition, based on the Distribution Channel segmentation, the Retail Sales segment is predicted to increase at the quickest rate throughout the projected period due to the expanding number of retail pharmacies.
• Finally, based on Region, Europe holds the significant market share within the Allergy Immunotherapy market in 2022 because of continuous efforts by the government and companies to develop new products.

Market Dynamics

The demand for Allergy Immunotherapy is increasing because there is a pressing need to address allergies caused by substances like pollens, dust mites, and insect venom. Allergic rhinitis, allergic skin diseases, food allergies, and asthma impact a significant portion of the population in Europe alone. This highlights a potential growth opportunity in the market for allergen immunotherapy. The demand for Allergy Immunotherapy is also rising globally, even in regions where allergies were previously less common.

People in the 20–40 age range are most likely to suffer from allergic problems, and a large proportion of them have rhinitis symptoms. As allergies become more widespread and life-threatening emergencies related to allergies increase, companies are actively developing new treatments to improve the lives of allergic patients. The Allergy Immunotherapy market is critical in addressing the worldwide healthcare challenges associated with allergies.

Europe secured the largest market share in 2022 and is expected to continue leading. This is because of the strong presence of essential market players. Currently, over 150 million people in Europe suffer from allergic illnesses, and by 2025, it is expected that over 50% of the population will have an allergy of some kind. Factors like industrialization, urbanization, climate change, and pollution influence this increase. The increase in approvals for allergy drops in this region also contributes to the region's dominant market share. For instance, SLIT is widely used as a treatment for allergen-specific immunotherapy in this region.

The Global Allergy Immunotherapy Market is Segmented as follows

• Type
  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
• Allergy Type
  • Allergic Rhinitis
  • Allergic Asthma
  • Food Allergy
  • Atopic Dermatitis
  • Other Allergy Types
• Distribution Channel
  • Institutional Sales
  • Retail Sales
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

List of the Key Players of the Global Allergy Immunotherapy Market is

Merck KGaA (Germany), Jubilant Pharma (Hollister Allergy) (U.S.), Leti Pharma (Spain), Stallergenes Greer (Switzerland), ALK-Abello A/S (Denmark), Allergy Therapeutics (UK), Anergis SA (Switzerland), ASIT Biotech (Belgium), DBV Technologies (France), HAL Allergy Group (Netherlands), Aimmune Therapeutics (U.S.), Arrayit Corporation (U.S.), Biomay AG (Austria) 

The Global Allergy Immunotherapy Market Scope can be Tabulated as below